Soligenix Faces Nasdaq Delisting Threat and Terminates Lead Drug Program
SNGX sits 54% above its 52-week low of $0.28 on light trading volume (0.1× avg).
Summary
Soligenix received a Nasdaq delisting notice and formally terminated its HyBryte™ drug development program, intensifying financial and operational challenges.
Key Events · Legal and Risk Events · SNGX
-
Nasdaq Delisting Notice Received
Soligenix received a notice from Nasdaq for non-compliance with the $1.00 minimum bid price rule, initiating a 180-day period to regain compliance by December 7, 2026.
-
HyBryte™ Development Program Terminated
Following the previously reported futility halt of its pivotal Phase 3 trial, the Board formally decided to terminate the HyBryte™ development program.
-
Strategic Options Under Review
With the termination of its lead program, the company will now evaluate strategic alternatives, including potential mergers, acquisitions, or advancing other pipeline assets.
-
Consulting CMO Role Ends
Dr. Richard Straube's role as Consulting Chief Medical Officer concluded, directly linked to the termination of the HyBryte™ program.
Analysis · SNGX · Life Sciences
Soligenix received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price, giving it until December 7, 2026, to regain compliance. This comes as the company formally terminates its HyBryte™ development program, a decision following the Phase 3 trial's futility halt in April. These events compound existing financial distress, including a going concern warning and ongoing dilutive ATM sales, forcing the company to explore strategic alternatives.
At the time of this filing, SNGX was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.